Probi’s Indian IBS study published in the World Journal of Gastroenterology

Both the intensity and the frequency of the key symptoms of Irritable Bowel
Syndrome (IBS) declined significantly following ingestion of Probi’s bacteria
Lactobacillus plantarum 299v. These are the principal findings of the Indian
study from 2009 on 214 IBS patients which has now been published in the World
Journal of Gastroenterology (WJG 2012 August 14; 18(30): 4012-4018).

The study was performed as a double-blind, randomised, placebo-controlled
parallel group over a period of four weeks and was concluded at the end of 2009.
Measurable symptoms including abdominal pain, bloating and frequency of bowel
movements improved significantly in the group receiving the active bacteria in
comparison with the placebo group.

Lactobacillus plantarum 299v is a probiotic strain that has previously been
shown to alleviate symptoms such as pain and flatulence in IBS patients (Nobaek
et al, Niedzielin et al). Lp299v is sold in all countries in which Probi’s
products have been launched and is the company’s single largest commercial
probiotic bacteria. Lp299v is available in Sweden as a food, in the fruit drink
ProViva, and as a dietary supplement under the brand ProbiMage.

“The publication of this study further strengthens our documentation of the
effects of Lp299v and the interest in Probi’s products in this area. The study
will be a key component of Probi’s application to the European Food Safety
Authority regarding a health claim in the EU in the area of gastrointestinal
health,” says Michael Oredsson, CEO of Probi.

The information is such that Probi AB is required to disclose in accordance with
the Swedish Securities Market Act and/or the Financial Instruments Trading Act.
This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.

FOR FURTHER INFORMATION, CONTACT:

Michael Oredsson, CEO, Probi, phone +46 46 286 89 23 or mobile +46 707 18 89 30
e-mail: michael.oredsson@probi.se
Niklas Larsson, Research Director, phone +46 46 286 89 21 or mobile +46 761 18
26 99
e-mail: niklas.larsson@probi.se

ABOUT PROBI

Probi is a leading player in probiotic research and the development of efficient
and well-documented probiotics. Its research areas include: gastrointestinal
tracts, immune system, metabolic syndrome and stress and recovery. Probi’s
customersare leading companies in the functional foods and consumer healthcare
business areas. Income for 2011 totalled MSEK 95.0. Probi’s share is listed on
the Nasdaq OMX Stockholm, Small Cap. Probi has approximately 5,000 shareholders.
For more information, please visit www.probi.com.